Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma - Drug Trials For Money - Paid Clinical Trials

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
Conditions:   Recurrent Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma
Interventions:   Biological: Basiliximab;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells;   Biological: Recombinant Granulocyte Colony-Stimulating Factor;   Biological: Yttrium Y 90 Basiliximab
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 5, 2021 / by / in
Comments